Aurobindo Pharma · NSE: AUROPHARMA · BSE: 524804

Q3 FY24 results · Oct–Dec 2023

Aurobindo Pharma reported revenue from operations of ₹7,351.78 crore (up 14.7% from Q3 FY23) and net profit of ₹939.97 crore (up 91.4% from Q3 FY23) for Q3 FY24 (Oct–Dec 2023), on a consolidated basis.

Consolidated · ₹ crore
Item	Q3 FY24	Q3 FY23	YoY	Q2 FY24	QoQ
Revenue from operations	7,351.78	6,407.13	+14.7%	7,219.42	+1.8%
Other income	162.52	92.65	+75.4%	186.98	−13.1%
Total income	7,514.30	6,499.78	+15.6%	7,406.40	+1.5%
Profit before share of associates & JVs and tax	1,265.01	680.70	+85.8%	1,074.74	+17.7%
Share of profit/(loss) of associates & JVs	(2.59)	(0.59)		0.90
Net profit for the period	939.97	491.01	+91.4%	751.94	+25.0%
Attributable to shareholders of the company	936.29	491.26	+90.6%	757.18	+23.7%
EPS, basic (₹)	16.04	8.38	+91.4%	12.83	+25.0%
Net margin (%)	12.8	7.7		10.4

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q3 FY24	Q3 FY23	YoY	Q2 FY24	QoQ
Revenue from operations	2,692.03	3,432.26	−21.6%	2,668.76	+0.9%
Other income	331.13	78.73	+320.6%	67.08	+393.6%
Total income	3,023.16	3,510.99	−13.9%	2,735.84	+10.5%
Profit before tax	687.22	404.49	+69.9%	509.78	+34.8%
Net profit for the period	623.78	298.82	+108.7%	415.74	+50.0%
EPS, basic (₹)	10.65	5.10	+108.8%	7.10	+50.0%
Net margin (%)	23.2	8.7		15.6

Consolidated

Filed with BSE: 12 Feb 2024, 10:55 IST
Board meeting: 10 Feb 2024
Period: 01 Oct 2023 to 31 Dec 2023
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 12 Feb 2024, 10:55 IST
Board meeting: 10 Feb 2024
Period: 01 Oct 2023 to 31 Dec 2023
Review status: Unaudited
Source: XBRL filing on BSE